Effects of the combination of insulin and glibenclamide in Type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents

[1]  L. Groop,et al.  The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes. , 1984, Acta endocrinologica.

[2]  S. Blumenthal.  Potentiation of the Hepatic Action of Insulin by Chlorpropamide , 1977, Diabetes.

[3]  Rizza Ra.  Combined sulfonylurea and insulin therapy in insulin-dependent diabetes: research or clinical practice? , 1985 .

[4]  D L Horwitz,et al.  Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics , 1977, Diabetes.

[5]  D. Schade,et al.  Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. , 1987, JAMA.

[6]  B. Burke,et al.  Stimulation of residual insulin secretion by glibenclamide in insulin dependent diabetics. , 1980, Acta endocrinologica.

[7]  J. Proietto,et al.  Differential effects of insulin therapy on hepatic and peripheral insulin sensitivity in Type 2 (non-insulin-dependent) diabetes , 1982, Diabetologia.

[8]  N. Nurjhan,et al.  Insulin Dose-Response Characteristics for Suppression of Glycerol Release and Conversion to Glucose in Humans , 1986, Diabetes.

[9]  L. Heding.  Radioimmunological determination of human C-peptide in serum , 1975, Diabetologia.

[10]  K. Osei,et al.  Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism. , 1984, The American journal of medicine.

[11]  D. Porte,et al.  Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. , 1976, The Journal of clinical endocrinology and metabolism.

[12]  R. Rizza.  Combined Sulfonylurea and Insulin Therapy in Insulin-dependent Diabetes: Research or Clinical Practice? , 1985, Diabetes Care.

[13]  J. Tobin,et al.  Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity. , 1982, The New England journal of medicine.

[14]  R. DeFronzo,et al.  Splanchnic and Peripheral Disposal of Oral Glucose in Man , 1983, Diabetes.

[15]  L. Groop,et al.  Different Effects of Glyburide and Glipizide on Insulin Secretion and Hepatic Glucose Production in Normal and NIDDM Subjects , 1987, Diabetes.

[16]  K. Minaker,et al.  Insulin dose-dependent reductions in plasma amino acids in man. , 1986, The American journal of physiology.

[17]  R. Bressler,et al.  Clinical Pharmacology of Oral Antidiabetic Agents , 1977 .

[18]  B. Volk,et al.  PHYSIOLOGICAL BASIS OF THE EFFECTIVENESS OF COMBINED INSULIN‐TOLBUTAMIDE THERAPY IN STABLE DIABETES * , 1959, Annals of the New York Academy of Sciences.

[19]  L. Groop,et al.  Effect of Glyburide on Glycemic Control, Insulin Requirement, and Glucose Metabolism in Insulin-Treated Diabetic Patients , 1987, Diabetes.

[20]  J. A. Scarlett,et al.  Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. , 1981, The Journal of clinical investigation.

[21]  L. Groop,et al.  Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. , 1985, Annals of clinical research.

[22]  E. Friedlander.  Use of tolbutamide in insulin-resistant diabetes; report of a case. , 1957, The New England journal of medicine.

[23]  B. Burke,et al.  Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide. , 1984, Acta endocrinologica.

[24]  R. DeFronzo,et al.  Regulation of Splanchnic and Peripheral Glucose Uptake by Insulin and Hyperglycemia in Man , 1983, Diabetes.

[25]  R. Schifman,et al.  Cholesterol in high-density lipoprotein: use of Mg2+/dextran sulfate in its enzymic measurement. , 1978, Clinical chemistry.

[26]  R. DeFronzo,et al.  Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia. , 1981, Acta endocrinologica.

[27]  J. Halter,et al.  The Effect of Chronic Sulfonylurea Therapy on Hepatic Glucose Production in Non-insulin-dependent Diabetes , 1982, Diabetes.

[28]  R. DeFronzo,et al.  Hepatic and peripheral insulin resistance: A common feature of Type 2 (non-insulin-dependent) and Type 1 (insulin-dependent) diabetes mellitus , 1982, Diabetologia.

[29]  R. Tattersall,et al.  The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? , 1984, British medical journal.

[30]  O. Owen,et al.  Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus. , 1986, Archives of internal medicine.

[31]  M. Fabrykant.  Favorable effects of supplemental orinase in insulin-treated labile diabetes. , 1957, Metabolism: clinical and experimental.

[32]  K. Schöffling,et al.  [Glibenclamide-insulin combination in the management of secondary failure of sulfonyl-urea medication]. , 2008, Deutsche medizinische Wochenschrift.

[33]  J. Olefsky,et al.  Metabolic Consequences of Very-Low-Calorie Diet Therapy in Obese Non-insulin-dependent Diabetic and Nondiabetic Subjects , 1986, Diabetes.

[34]  L. Groop,et al.  Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone. , 2009, Acta medica Scandinavica.

[35]  E. Haupt,et al.  [Secondary failures in modern therapy of diabetes mellitus with blood glucose lowering sulfonamides (author's transl)]. , 1977, Medizinische Klinik.

[36]  B V Howard,et al.  Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. , 1984, The Journal of clinical investigation.

[37]  H. Lebovitz,et al.  Appraisal of the extrapancreatic actions of sulfonylureas. , 1969, Archives of internal medicine.

[38]  K. Polonsky,et al.  C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. , 1984, The Journal of clinical investigation.

[39]  M. Riddle.  NEW TACTICS FOR TYPE 2 DIABETES: REGIMENS BASED ON INTERMEDIATE-ACTING INSULIN TAKEN AT BEDTIME , 1985, The Lancet.